國家衛生研究院 NHRI:Item 3990099045/15280

NHRI > National Institute of Infectious Diseases and Vaccinology > Min-Shi Lee > Conference Papers/Meeting Abstract > Item 3990099045/15280

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/15280

Title:	Development of seasonal influenza virus-like particle (VLP) vaccines using insect cell-based baculovirus expressing system
Authors:	Badruzzaman, ATM;Cheng, YC;Sung, WC;Huang, CY;Lee, MS
Contributors:	National Institute of Infectious Diseases and Vaccinology
Abstract:	Intro: Influenza viruses are highly infectious and cause widespread respiratory diseases. Moreover, it could pose a noteworthy epidemic and pandemic threat to public health. Vaccination is the most cost-effective intervention to prevent influenza and its complications. Currently, most commercial influenza vaccines are produced using embryonic chicken eggs (ECE), which is hard to scale up efficiently and could potentially reduce vaccine efficacy due to gene mutations in HA genes. In addition, the egg-based technology is associated with some jeopardy of allergic reactions and there is a risk of disrupted egg supply when avian influenza outbreaks erupt. To overcome the dependency on ECE, developments of influenza vaccines based on efficient and robust production platforms are urgently needed. Methods: Several potential vaccine production systems already have shown potential as replacers, including a virus-like particle (VLP) platform. In the current study, using a Baculovirus Expression System (BES), we engineered HA, NA, and M1 genes of influenza A/H1N1, A/H3N2, B/Yamagata-like, and B/Victoria-like virus strains (A/Hawaii/70/2019, A/Minnesota/41/2019, B/Brisbane/09/2014 & B/Brisbane/63/2014) to produce VLP vaccine antigens H1N1-VLP, H3N2-VLP, Yamagata-VLP, Victoria-VLP, respectively. Then functional and antigenic features were determined, including hemagglutination assay, protein composition, size, and morphology of the VLP antigens. Findings: We found that these recombinants VLPs contained influenza HA, NA, and M1 with functional activity, resembled influenza virions in morphology and size, and were structurally intact. We compared the immunogenicity of in-house VLP antigens and commercial recombinant HA (rHA) vaccines in mice. Results revealed that our recombinant VLP antigens are highly immunogenic and produced higher hemagglutination inhibition and virus neutralization antibody titers than the commercial rHA vaccine. Conclusion: The insect cell-based seasonal influenza VLP vaccine antigens are more immunogenic than rHA antigens. Further animal challenge studies are worth to conduct.
Date:	2023-05
Relation:	International Journal of Infectious Diseases. 2023 May;130(Suppl. 2):S81-S82.
Link to:	http://dx.doi.org/10.1016/j.ijid.2023.04.202
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1201-9712&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:001037898500191
Appears in Collections:	[Min-Shi Lee] Conference Papers/Meeting Abstract [Wang-Chou Sung] Conference Papers/Meeting Abstract

Files in This Item:

File	Description	Size	Format
ISI001037898500191.pdf		105Kb	Adobe PDF	146	View/Open

Loading...